{"id":429939,"date":"2019-09-19T09:28:01","date_gmt":"2019-09-19T09:28:01","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=429939"},"modified":"2019-09-19T09:28:01","modified_gmt":"2019-09-19T09:28:01","slug":"acute-myeloid-leukemia-treatment-market-2019-tremendous-growth-key-vendors-profile-top-regional-analysis-and-forecasts-till-2023","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-myeloid-leukemia-treatment-market-2019-tremendous-growth-key-vendors-profile-top-regional-analysis-and-forecasts-till-2023_429939.html","title":{"rendered":"Acute Myeloid Leukemia Treatment Market 2019 | Tremendous Growth, Key Vendors Profile, Top Regional Analysis and Forecasts Till 2023"},"content":{"rendered":"
\"Acute<\/a><\/div>\n
Global Acute Myeloid Leukemia Treatment Market Information; by Disease Type (Myeloblastic, Promyeloctic, Myelomonocytic, Monocytic, Erythroleukemia, Megakaryocytic)<\/div>\n

Market Highlights<\/strong><\/p>\n

The acute myeloid leukemia (AML) treatment market is rising due to increased stem cell transplant rates and a number of research pipeline drugs. Most patients are geriatrics aged 65 or over. Population with certain genetic disorders such as Shwachman syndrome, Diamond Blackfan Syndrome, Down syndrome, and certain blood disorders have greater chances of developing AML.<\/p>\n

However high disease heterogeneity leads to a lack of standardized treatment which hinders the market for AML drugs. The generics such as cytarabine and daunorubicin are dominating the treatment which is being challenged by the new drug developments such as enzyme targeted and anti-tumor-associated antigens\/genes therapies such as serine-threonine proteins kinases. However, the heterogeneity of cancer genes causing AML is making this approach difficult. Stem cell transplants (SCT) have been hampered by high treatment-related mortality rates especially for old patients who cannot tolerate it.<\/p>\n

Global Acute Myeloid Leukemia Treatment Market Is Expected To Grow At A CAGR Of 5.3% by 2023<\/p>\n

Get a free sample @ https:\/\/www.marketresearchfuture.com\/sample_request\/3223<\/a><\/em><\/strong><\/p>\n

A problem of identification of stem cells in heterogeneous diseases such as AML which contains small numbers of cancerous stem cells in bone marrow tissues that could contain thousands of different cells is difficult, complex as well as expensive. Understanding of stem cell control and regulation has not reached the level that is desired. However, future growth will be led by targeted therapies.<\/p>\n

The market driving factors are the rising number of stem cell banks and the increase in genetic profiling of cancer genes which is increasing the understanding of AML. The increasing interest and expenditure, as well as grants for stem cell research, will lead to future growth due to their high potential.<\/p>\n

Global Acute Myeloid Leukemia Treatment: SWOT Analysis<\/strong><\/p>\n